Exact Sciences Beheer

Beheer criteriumcontroles 2/4

De CEO Exact Sciences is Kevin Conroy, benoemd in Apr2009, heeft een ambtstermijn van 15.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.12M, bestaande uit 6.5% salaris en 93.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.4% van de aandelen van het bedrijf, ter waarde R$ 234.40M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.7 jaar.

Belangrijke informatie

Kevin Conroy

Algemeen directeur

US$16.1m

Totale compensatie

Percentage CEO-salaris	6.5%
Dienstverband CEO	15.6yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kevin Conroy's beloning veranderd ten opzichte van Exact Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$214m
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$16m	US$1m	-US$204m
Sep 30 2023	n/a	n/a	-US$282m
Jun 30 2023	n/a	n/a	-US$432m
Mar 31 2023	n/a	n/a	-US$517m
Dec 31 2022	US$14m	US$510k	-US$624m
Sep 30 2022	n/a	n/a	-US$716m
Jun 30 2022	n/a	n/a	-US$735m
Mar 31 2022	n/a	n/a	-US$745m
Dec 31 2021	US$15m	US$963k	-US$596m
Sep 30 2021	n/a	n/a	-US$793m
Jun 30 2021	n/a	n/a	-US$829m
Mar 31 2021	n/a	n/a	-US$720m
Dec 31 2020	US$20m	US$499k	-US$824m
Sep 30 2020	n/a	n/a	-US$327m
Jun 30 2020	n/a	n/a	-US$165m
Mar 31 2020	n/a	n/a	-US$136m
Dec 31 2019	US$19m	US$792k	-US$213m
Sep 30 2019	n/a	n/a	-US$216m
Jun 30 2019	n/a	n/a	-US$221m
Mar 31 2019	n/a	n/a	-US$219m
Dec 31 2018	US$7m	US$696k	-US$175m
Sep 30 2018	n/a	n/a	-US$143m
Jun 30 2018	n/a	n/a	-US$124m
Mar 31 2018	n/a	n/a	-US$119m
Dec 31 2017	US$13m	US$633k	-US$114m

Compensatie versus markt: De totale vergoeding ($USD 16.12M ) Kevin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.73M ).

Compensatie versus inkomsten: De vergoeding van Kevin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Kevin Conroy (58 yo)

15.6yrs

Tenure

US$16,119,899

Compensatie

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Conroy	Chairman of The Board & CEO	15.6yrs	US$16.12m	0.40% R$ 234.4m
Jake Orville	Executive VP & GM of Screening	no data	US$3.67m	0.0084% R$ 5.0m
Brian Baranick	Executive VP & General Manager of Precision Oncology	no data	US$3.57m	0.0071% R$ 4.2m
Aaron Bloomer	Executive Vice President of Finance	less than a year	geen gegevens	geen gegevens
Jorge Garces	Chief Science Officer	3.6yrs	geen gegevens	geen gegevens
Nassar Nizami	Chief Information Officer	1.8yrs	geen gegevens	geen gegevens
Megan Jones	Associate Manager of Investor Relations	no data	geen gegevens	geen gegevens
Tim Caprez	Chief Compliance Counsel & VP	9.8yrs	geen gegevens	geen gegevens
James Herriott	Senior VP	2.8yrs	geen gegevens	0.0060% R$ 3.5m
Sarah Condella	Executive Vice President of Human Resources	7.5yrs	US$2.71m	0.042% R$ 25.1m
Graham Lidgard	Emeritus Chief Science Officer	3.8yrs	US$4.21m	geen gegevens
Ana Hooker	Chief Laboratory Officer	9.3yrs	US$3.95m	geen gegevens

3.8yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van E2XA34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Conroy	Chairman of The Board & CEO	15.7yrs	US$16.12m	0.40% R$ 234.4m
Daniel Levangie	Independent Director	14.3yrs	US$408.75k	0.015% R$ 9.1m
D. Coward	Director	1.9yrs	US$1.47m	0.030% R$ 17.6m
Katherine Zanotti	Independent Director	15.6yrs	US$406.25k	0.038% R$ 22.5m
Michael Barber	Independent Director	less than a year	geen gegevens	0.0029% R$ 1.7m
Paul Clancy	Independent Director	3.7yrs	US$417.75k	0.011% R$ 6.5m
Kathleen Sebelius	Independent Director	5.7yrs	US$411.75k	0.017% R$ 10.2m
Shacey Petrovic	Independent Director	4.3yrs	US$401.25k	0.012% R$ 7.4m
James Doyle	Lead Independent Director	10.3yrs	US$442.75k	0.030% R$ 17.8m

5.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van E2XA34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).

Exact Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corporation Announces Executive Changes

Recent updates

Exact Sciences Corporation Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exact Sciences Corporation to Report Q3, 2024 Results on Nov 05, 2024

FDA Approves Exact Sciences Corp.’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Corporation(NasdaqCM:EXAS) dropped from FTSE All-World Index (USD)

Exact Sciences Presents Data Demonstrating Advancement in Blood-Based Colorectal Cancer Screening At ESMO 2024

Exact Sciences Corp. Announces First Patient Enrolled in Its Multi-Cancer Early Detection Falcon Registry Real-World Evidence Study

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year 2024

Exact Sciences Corporation to Report Q2, 2024 Results on Jul 31, 2024

Geneoscopy, Inc. Files Counterclaims Against Exact Sciences

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation announced that it expects to receive $266.8 million in funding

Exact Sciences Corporation to Report Q1, 2024 Results on May 08, 2024

Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Exact Sciences Corporation to Report Q4, 2023 Results on Feb 21, 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023

Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial

Exact Sciences Corporation to Report Q3, 2023 Results on Nov 01, 2023

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

Exact Sciences Corporation Announces Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corp. Announces Positive Top-Line Results from the Pivotal Blue-C Study

Exact Sciences Corp. Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO 2023

Consensus Cloud Solutions, Inc. Revises Earnings Guidance for the Year 2023

Exact Sciences Corporation to Report Q4, 2022 Results on Feb 21, 2023

Exact Sciences Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

Exact Sciences Corporation Reports Impairment Charges for the Third Quarter Ended September 30, 2022

Exact Sciences Corporation to Report Q3, 2022 Results on Nov 03, 2022

Exact Sciences Corp. Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation At the 2022 European Society for Medical Oncology Congress

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Exact Sciences Corporation to Report Q2, 2022 Results on Aug 02, 2022

American Society of Clinical Oncology Guidelines Strong Recommendation of Use of the Oncotype DX Breast Recurrence Score® Test of Exact Sciences Corp. in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Exact Sciences Corporation Raises Revenue Guidance for the Year 2022

Exact Sciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

Exact Sciences Corporation Provides Earnings Guidance for the Year 2022

Exact Sciences Corporation to Report Q4, 2021 Results on Feb 22, 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd